ReviewFrontiers in cell and developmental biology2026
Stromal or exosome derived lncRNAs regulate stemness in hepatocellular carcinoma.
Review in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatocellular carcinoma (HCC) remains one of the most prevalent malignancies worldwide, with high recurrence rates and chemotherapy resistance posing major clinical challenges. Cancer stem cells (CSCs) are recognized as an important contributors of HCC initiation, metastasis, and recurrence. Within the tumor microenvironment (TME), cancer-associated fibroblasts (CAFs) can maintain CSC properties through intercellular communication. Exosomes serve as essential mediators of this process by delivering long noncoding RNAs (lncRNAs) from various TME cells (including CAFs, MSCs, macrophages, and HCC cells themselves) to recipient HCC cells. Methods: A literature search of PubMed and Web of Science Core Collection (inception to March 2026) was conducted using key terms including "HCC", "CAFs", "MSCs", "Macrophages", "Exosome", "LncRNA", and "Neoplastic Stem Cells". Studies were selected based on topic relevance and methodological rigor; those with incomplete or inaccessible data were excluded. The retrieved literature was synthesized to elucidate the mechanisms by which lncRNAs modulate downstream signaling pathways and to evaluate their translational potential as diagnostic biomarkers and therapeutic targets. Results: This review identifies multiple mechanisms through which stromal or exosome derived lncRNAs regulate HCC cell stemness, including YAP liquid-liquid phase separation, chromatin remodeling via recruitment of SWI/SNF, INO80, NuRD, and BRM/BRG1 complexes, Wnt/β-catenin pathway modulation through protein stabilization and competing endogenous RNA (ceRNA) networks, STAT3 pathway regulation via direct transcriptional repression and transcription factor recruitment, and BMP signaling pathway engagement. Functional classification reveals that these lncRNAs converge on core stemness pathways through complementary transcriptional, posttranscriptional, and protein-level regulatory mechanisms, while integrating signals from the TME. Conclusion: Stromal or exosome derived lncRNAs constitute a critical regulatory layer in HCC stemness maintenance and hold significant promise as noninvasive diagnostic biomarkers via liquid biopsy. Antisense oligonucleotide (ASO)-based therapeutic strategies targeting the stromal cell-lncRNA-CSC axis represent a promising direction. Nevertheless, systematic characterization of stromal or exosome derived lncRNA species, elucidation of lncRNA sorting and uptake mechanisms, and clinical validation of biomarker and therapeutic applications remain important challenges for future investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.